These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18077531)

  • 1. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.
    Tseng JR; Kang KW; Dandekar M; Yaghoubi S; Lee JH; Christensen JG; Muir S; Vincent PW; Michaud NR; Gambhir SS
    J Nucl Med; 2008 Jan; 49(1):129-134. PubMed ID: 18077531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of a novel c-Met inhibitor in a gastric cancer xenograft model using small animal PET.
    Wiehr S; von Ahsen O; Röse L; Mueller A; Mannheim JG; Honndorf V; Kukuk D; Reischl G; Pichler BJ
    Mol Imaging Biol; 2013 Apr; 15(2):203-11. PubMed ID: 22864665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.
    Rex K; Lewis XZ; Gobalakrishnan S; Glaus C; Silva MD; Radinsky R; Burgess TL; Gambhir SS; Coxon A
    Nucl Med Biol; 2013 May; 40(4):458-63. PubMed ID: 23454250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts.
    Dandekar M; Tseng JR; Gambhir SS
    J Nucl Med; 2007 Apr; 48(4):602-7. PubMed ID: 17401098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
    J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
    Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
    J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
    Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
    World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
    Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
    Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
    McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
    J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo responses of human A375M melanoma to a σ ligand: 18F-FDG PET imaging.
    Rybczynska AA; de Bruyn M; Ramakrishnan NK; de Jong JR; Elsinga PH; Helfrich W; Dierckx RA; van Waarde A
    J Nucl Med; 2013 Sep; 54(9):1613-20. PubMed ID: 23940303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET.
    Geven EJ; Evers S; Nayak TK; Bergström M; Su F; Gerrits D; Franssen GM; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(3):203-10. PubMed ID: 25204436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
    Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.
    Chang E; Liu H; Unterschemmann K; Ellinghaus P; Liu S; Gekeler V; Cheng Z; Berndorff D; Gambhir SS
    Clin Cancer Res; 2015 Jan; 21(2):335-46. PubMed ID: 25381339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
    Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
    J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG small animal PET permits early detection of malignant cells in a xenograft murine model.
    Nanni C; Di Leo K; Tonelli R; Pettinato C; Rubello D; Spinelli A; Trespidi S; Ambrosini V; Castellucci P; Farsad M; Franchi R; Pession A; Fanti S
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):755-762. PubMed ID: 17160412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
    Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
    Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
    Goggi JL; Bejot R; Moonshi SS; Bhakoo KK
    J Nucl Med; 2013 Sep; 54(9):1630-6. PubMed ID: 23907757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Eschbach RS; Kazmierczak PM; Heimer MM; Todica A; Hirner-Eppeneder H; Schneider MJ; Keinrath G; Solyanik O; Olivier J; Kunz WG; Reiser MF; Bartenstein P; Ricke J; Cyran CC
    Cancer Imaging; 2018 Jan; 18(1):2. PubMed ID: 29347968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice.
    Lee KH; Ko BH; Paik JY; Jung KH; Choe YS; Choi Y; Kim BT
    J Nucl Med; 2005 Sep; 46(9):1531-6. PubMed ID: 16157537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.